Nykode Therapeutics AS (OSL:NYKD)

Nykode Therapeutics AS Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 12, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	970	788	995	6,988	8,287	23,372
Market Cap Growth	14.67%	-20.81%	-85.77%	-15.67%	-64.54%	9.44%
Enterprise Value	388	178	-270	5,353	6,040	21,724
Last Close Price	2.97	2.41	1.99	13.98	18.37	52.72
Forward PE	-	-	-	-	4.32	4.32
PS Ratio	212.38	172.48	9.56	51.73	93.16	74.18
PB Ratio	1.05	0.85	0.64	4.02	5.36	13.67
P/TBV Ratio	1.05	0.85	0.64	4.03	5.36	13.67
P/FCF Ratio	-	-	-	-	-	9341.31
P/OCF Ratio	-	-	-	-	-	2296.91
EV/Sales Ratio	84.92	38.99	-	39.62	67.90	68.94
EV/FCF Ratio	-1.30	-	-	-	-	8682.61
Debt / Equity Ratio	0.03	0.03	0.03	0.03	0.04	0.04
Debt / FCF Ratio	-	-	-	-	-	25.25
Net Debt / Equity Ratio	-0.63	-0.63	-0.82	-0.92	-1.28	-1.14
Net Debt / EBITDA Ratio	2.07	2.07	2.35	2.73	3.81	20.70
Net Debt / FCF Ratio	1.96	1.96	2.18	1.59	8.60	-778.98
Asset Turnover	0.00	0.00	0.05	0.06	0.04	0.14
Quick Ratio	9.99	9.99	12.78	7.94	5.41	8.12
Current Ratio	9.99	9.99	12.87	8.04	5.44	8.16
Return on Equity (ROE)	-10.75%	-10.75%	-25.25%	-21.42%	-24.35%	-5.05%
Return on Assets (ROA)	-14.10%	-14.10%	-16.70%	-16.90%	-13.64%	-2.72%
Return on Invested Capital (ROIC)	-79.39%	-98.49%	-250.18%	-	-	-
Return on Capital Employed (ROCE)	-30.50%	-30.50%	-33.50%	-31.00%	-29.10%	-4.60%
Earnings Yield	-12.72%	-15.67%	-44.34%	-5.10%	-5.08%	-0.36%
FCF Yield	-30.66%	-37.75%	-58.58%	-14.30%	-2.78%	0.01%
Dividend Yield	33.67%	-	50.26%	-	-	-
Buyback Yield / Dilution	6.29%	6.29%	-8.66%	-3.58%	-1.32%	3.31%
Total Shareholder Return	39.96%	6.29%	41.60%	-3.58%	-1.32%	3.31%

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.